0001415889-24-004471.txt : 20240220 0001415889-24-004471.hdr.sgml : 20240220 20240220183647 ACCESSION NUMBER: 0001415889-24-004471 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240215 FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rhodes Jason P CENTRAL INDEX KEY: 0001577014 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 24655597 MAIL ADDRESS: STREET 1: C/O EPIZYME, INC. STREET 2: 400 TECHNOLOGY SQUARE, 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-02202024_110236.xml X0508 4 2024-02-15 0001818794 Dyne Therapeutics, Inc. DYN 0001577014 Rhodes Jason P C/O DYNE THERAPEUTICS, INC. 830 WINTER ST. WALTHAM MA 02451 true false false false 1 Common Stock 2024-02-15 4 S 0 175793 23.88 D 7150324 I See footnote Common Stock 2024-02-15 4 S 0 2113 24.45 D 7148211 I See footnote Common Stock 2024-02-16 4 S 0 162707 23.14 D 6985504 I See footnote Common Stock 2024-02-20 4 S 0 166029 22.71 D 6819475 I See footnote Common Stock 2024-02-20 4 S 0 3510 23.40 D 6815965 I See footnote Common Stock 1608785 I See footnote Common Stock 934581 I See footnote This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.40 to $24.3943 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6) and (7). The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.40 to $24.51 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.878 to $23.54 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.117 to $23.09 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.16 to $24.01 inclusive. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The reporting person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any. The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. /s/ Jason Rhodes 2024-02-20